Cargando…

Antibody therapies for the prevention and treatment of viral infections

Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Salazar, Georgina, Zhang, Ningyan, Fu, Tong-Ming, An, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627241/
https://www.ncbi.nlm.nih.gov/pubmed/29263875
http://dx.doi.org/10.1038/s41541-017-0019-3
_version_ 1783268678083543040
author Salazar, Georgina
Zhang, Ningyan
Fu, Tong-Ming
An, Zhiqiang
author_facet Salazar, Georgina
Zhang, Ningyan
Fu, Tong-Ming
An, Zhiqiang
author_sort Salazar, Georgina
collection PubMed
description Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.
format Online
Article
Text
id pubmed-5627241
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56272412017-12-20 Antibody therapies for the prevention and treatment of viral infections Salazar, Georgina Zhang, Ningyan Fu, Tong-Ming An, Zhiqiang NPJ Vaccines Review Article Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline. Nature Publishing Group UK 2017-07-10 /pmc/articles/PMC5627241/ /pubmed/29263875 http://dx.doi.org/10.1038/s41541-017-0019-3 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Salazar, Georgina
Zhang, Ningyan
Fu, Tong-Ming
An, Zhiqiang
Antibody therapies for the prevention and treatment of viral infections
title Antibody therapies for the prevention and treatment of viral infections
title_full Antibody therapies for the prevention and treatment of viral infections
title_fullStr Antibody therapies for the prevention and treatment of viral infections
title_full_unstemmed Antibody therapies for the prevention and treatment of viral infections
title_short Antibody therapies for the prevention and treatment of viral infections
title_sort antibody therapies for the prevention and treatment of viral infections
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627241/
https://www.ncbi.nlm.nih.gov/pubmed/29263875
http://dx.doi.org/10.1038/s41541-017-0019-3
work_keys_str_mv AT salazargeorgina antibodytherapiesforthepreventionandtreatmentofviralinfections
AT zhangningyan antibodytherapiesforthepreventionandtreatmentofviralinfections
AT futongming antibodytherapiesforthepreventionandtreatmentofviralinfections
AT anzhiqiang antibodytherapiesforthepreventionandtreatmentofviralinfections